Press Release
-
Non-Invasive Precision Monitoring of Tumors and Early Cancer Detection Using Methylated Free DNA in Blood
Introducing the All-seeing Eye, a groundbreaking technology that detects methylated circulating cell-free DNA released from tumors undergoing apoptosis, necrosis, and secretion into the bloodstream. This innovative approach allows for the non-invasive monitoring of cancer progression by capturing these tumor-derived DNA fragments circulating in the blood. By focusing on the methylation patterns specific to cancer cells,…
-
EG BioMed R&D Team Discovers the Key to Revolutionizing Breast Cancer Monitoring
Discovering the perfect biomarker for cancer progression is like finding a needle in a haystack. But with cutting-edge genomic technologies and a global perspective, we’ve found that needle. Through the use of Illumina methylation arrays, researchers analyzed breast tumor samples from Taiwanese patients and cross-referenced them with data from The Cancer Genome Atlas (TCGA) in…
-
Taiwan’s Medical Milestone! EG BioMed’s Innovative Pancreatic Cancer Blood Test Shines on the International Stage
EG BioMed has achieved a significant breakthrough in the field of pancreatic cancer detection with its innovative EG-Pancreatic Blood Test-E1 technology. This cutting-edge technology has received high praise from international experts and was prominently featured in the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting under Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary. Additionally, it was…